EyePoint Pharmaceuticals, Inc. (EYPT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 5,333 | 24,453 | 10,524 | |
| Sales and marketing | 35 | 35 | 24 | |
| Research and development | 55,498 | 58,574 | 29,542 | |
| General and administrative | 11,862 | 13,876 | 12,970 | |
| Cost of sales | 165 | 805 | - | |
| Total operating expenses | 67,560 | 73,290 | - | |
| Cost of goods and services sold, total | - | - | 736 | |
| Costs and expenses | - | - | 43,272 | |
| Loss from operations | -62,227 | -48,837 | -32,748 | |
| Interest and other income, net | - | - | 3,387 | |
| Interest and other income, net | 2,894 | 3,642 | - | |
| Total other income, net | 2,894 | 3,642 | 3,387 | |
| Net loss before income taxes | -59,333 | - | - | |
| Provision for income taxes | 93 | - | - | |
| Net loss | -59,426 | -45,195 | -29,361 | |
| Unrealized gain (loss) on available-for-sale securities | -91 | -105 | 379 | |
| Comprehensive income (loss) | -59,517 | -45,300 | -28,982 | |
| Net loss per share - basic | -0.85 | -0.65 | -0.54 | |
| Net loss per share - diluted | -0.85 | -0.65 | -0.54 | |
| Weighted average common shares outstanding - basic | 69,926 | 69,767,000 | 54,449,000 | |
| Weighted average common shares outstanding - diluted | 69,926 | 69,767,000 | 54,449,000 | |